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Aim: To investigate the therapeutic potential for treating inner ear damage of two new
steroidal alkaloid compounds, Dendrogenin A and Dendrogenin B, previously shown to
be potent inductors of cell differentiation.
Methods: Guinea pigs, unilaterally deafened by neomycin infusion, received a cochlear
implant followed by immediate or a 2-week delayed treatment with Dendrogenin
A, Dendrogenin B, and, as comparison artificial perilymph and glial cell-line derived
neurotrophic factor. After a 4-week treatment period the animals were sacrificed and the
cochleae processed for morphological analysis. Electrically-evoked auditory brainstem
responses (eABRs) were measured weekly throughout the experiment.
Results: Following immediate or delayed Dendrogenin treatment the electrical
responsiveness was significantly maintained, in a similar extent as has been shown
using neurotrophic factors. Histological analysis showed that the spiral ganglion neurons
density was only slightly higher than the untreated group.
Conclusions: Our results suggest that Dendrogenins constitute a new class of
drugs with strong potential to improve cochlear implant efficacy and to treat
neuropathy/synaptopathy related hearing loss. That electrical responsiveness was
maintained despite a significantly reduced neural population suggests that the efficacy
of cochlear implants is more related to the functional state of the spiral ganglion neurons
than merely their number.
Keywords: auditory nerve, cochlear implant, spiral ganglion neuron, steroidal alkaloid, electrically-evoked auditory
brainstem response
Introduction
The biological properties of two new alkylaminooxysterols have been characterized by de
Medina et al. (2009). One, 5α-Hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-
3beta-ol, called Dendrogenin A (DDA), the first steroidal alkaloid identified in mammals,
was shown to induce growth control, differentiation, and the death of tumor cell lines. The
other, 5α-Hydroxy-6β-[3-(4-aminobutylamino)-propylamino]cholest-7-en-3beta-ol, named
Dendrogenin B (DDB), induced neurite outgrowth on various cell lines, neuronal differentiation
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in pluripotent cells, and survival of normal motor neurons at
nanomolar concentrations. Based on the in vitro results, it was
hypothesized that the compounds could be used to influence
neurodegenerative processes. One of the most common sensory
deficits, hearing impairment, involves a progressive degeneration
of structures within the inner ear, including the auditory nerve
fibers and subsequently the spiral ganglion neurons themselves.
The neural degeneration is usually caused by the loss of the
target cells, the inner hair cells within the sensory epithelium.
Damage to the hair cells results in hearing impairment that,
however, can be functionally compensated for by implanting
a cochlear prosthesis providing electrical stimulation of the
nerve fibers, thus bypassing the dysfunctional sensory cells. The
emergence of the cochlear prosthesis has provided great benefit
to many hearing impaired patients and is now an established
therapy worldwide. However, the progressive peripheral nerve
fiber regression and subsequent degeneration of the cells in the
spiral ganglion can diminish its efficacy (Maruyama et al., 2008;
Fransson et al., 2010). Consequently, drugs that maintain the
structural and functional integrity of the auditory neurons are
thus likely to further improve the benefits of cochlear implant
for hearing impaired patients.
To test the neural effects of Dendrogenins in a functionally
intact system, an experimental model of the guinea pig inner
ear was used. This model, originally developed to mimic a
severely deaf patient being implanted with a cochlear prosthesis
(cochlear implant), has been used to demonstrate positive effects
on auditory neurons of various neurotrophic factors infused to
the inner ear (Shinohara et al., 2002; Maruyama et al., 2008;
Jørgensen et al., 2012). In this model, cochlear implant efficacy,
measured as the electrical responsiveness of the auditory nervous
system, is related to the functional preservation of the spiral
ganglion neurons.
There are several experimental reports demonstrating that
the progressive loss of spiral ganglion neurons results in
reduced electrical responsiveness of the neurons and thus
reduced efficacy of electrical stimulation (Shinohara et al.,
2002; Scheper et al., 2009). The results have suggested that
cochlear implant efficacy is closely related to the number of
remaining spiral ganglion neurons. For instance, it has been
shown that intracochlear infusion of trophic factors such as
glial cell-line neurotrophic factor (GDNF) and brain-derived
neurotrophic factor preserve the spiral ganglion population and
maintain the electrical responsiveness of the system (Shepherd
et al., 2005; Maruyama et al., 2008; Agterberg et al., 2009;
Fransson et al., 2010). Other reports, however, have suggested
a less direct relationship between the electrical responsiveness
of the inner ear and the number of remaining spiral ganglion
neurons (Simmons, 1979; Miller et al., 1983). Indeed, the spatial
proximity between cochlear implant electrodes and the neural
peripheral processes appeared to be a highly relevant factor for
optimal transfer of electrical impulses. Based on this notion, the
induction of axonal regrowth (sprouting) on remaining spiral
ganglion neurons constitutes an interesting therapeutic strategy
to improve the efficacy of cochlear implants (Roehm andHansen,
2005; Wilson and Dorman, 2008; Shibata et al., 2011). This
has been shown with NT3 (Malgrange et al., 1996; Wang and
Green, 2011) or BDNF treatment (Shibata et al., 2010). In the
present report, we explore the biological activity of the two
newly synthesized alkylaminooxysterols DDA and DDB using
the guinea pig model. Our results demonstrate positive effects
on electrical responsiveness, similar to what has been shown for




The guinea pig model mimics the situation in a severely
deaf patient being treated with a cochlear implant (Shinohara
et al., 2002). The animals are unilaterally deafened by infusing
an ototoxic compound (neomycin sulfate) into the inner ear
to damage the sensory hair cells and initiate a secondary
degeneration of the spiral ganglion neurons. An electrode is then
introduced into the fluid filled scala tympani of the cochlea to
electrically stimulate the remaining neurons and nerve fibers.
Resulting auditory function is evaluated by recording electrically-
evoked auditory brainstem responses (eABRs), over time. In
the present study, Dendrogenins were infused directly into
scala tympani and the cochlear fluid, perilymph, by means of
mini-osmotic pumps, either shortly after deafening (Immediate
Treatment) or after a longer time period when the spiral
ganglion neuron degeneration is expected to be more severe
(Delayed Treatment). In the first study (Immediate Treatment)
neomycin was infused for 48 h prior to an immediate 4-week
infusion period with DDA, DDB, and for comparison, GDNF.
Infusion of artificial perilymph (AP, Ringer’s acetate), served
as control. Following a subsequent 2-week period without
any drug delivery, the animals were sacrificed for structural
analysis. In the second study (Delayed Treatment), drug
infusion started 2 weeks after initiating the deafening process.
Throughout the experiment eABRs were measured weekly to
monitor the electrical responsiveness of the peripheral auditory
system.
Subjects
A total of 53 pigmented guinea pigs of both sexes (270–420 g;
Lidköpings Kaninfarm, Lidköping, Sweden) were used. Prior
to surgery all the animals were tested for the Preyer reflex, a
startle response to auditory stimuli frequently used to confirm
normal auditory function. All animal procedures were performed
in accordance with the ethical guidelines of Karolinska Institutet
and consistent with national regulations for care and use of
animals. The ethical permit was approved by Stockholms Norra
Djurförsöksetiska Nämnd, with ethical approval N 468/03 and
N 35/07.
Implantation Surgery
The animals included in the two studies received a stimulation
electrode and an infusion cannula by a surgical approach as
described previously (Brown et al., 1993; Fransson et al., 2009).
Guinea pigs were anesthetized using xylazine (10 mg/kg i.m.)
and ketamine (40 mg/kg i.m.). To confirm the depth of the
anestitic the guinea pigs ear was pinched and if the animal
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didn’t react it was considered to be deep asleep. Before surgery
a local anesthetic xylocain was injected subcutaneously on the
head, neck, behind the ear and on the back. To obstruct pain
after surgery the animals received Temgesic (Buprenorphine),
0.05 mg/kg for 48 h. The middle ear cavity was opened to
visualize the cochlea and to introduce the stimulation electrode
and the infusion cannula connected to the osmotic pump. The
active electrode was inserted into scala tympani through the
round window membrane and the ground electrode were placed
against the wall in the middle ear cavity. A small hole was drilled
in the basal turn of the cochlea and the infusion cannula was
inserted. The cannula was primed with 24 µl of a 10% neomycin
sulfate solution for cochlear infusion for 48 h with a flow rate
of 0.5 µl/h prior to the subsequent administration of the test
substances or AP.
Drug Delivery
Study I (Immediate Treatment): For the intracochlear infusion,
a pre-loaded cannula containing 24 µl of 10% neomycin sulfate
was connected to a mini-osmotic pump (ALZET 2002, DURECT
Corp., CA, USA) with a flow rate of 0.5 µl/h. After 48 h the
cochlea was infused with DDA (1 µM), DDB (1 µM), GDNF
(1 µg/ml), or AP that served as a control substance. After 2
weeks the pumpwas removed and exchanged to a new pre-loaded
pump filled with the same substance and left in place for another
2 weeks. After a total of 4 weeks of treatment the pump was
removed and the cannula sealed. The animals remained in the
study for an additional 2 weeks.
Study II (Delayed Treatment): The deafening procedure was
the same as for Study I but after the initial 48-h neomycin
infusion, no active treatment was initiated. Instead the cochlea
was infused with AP for 2 weeks using a mini-osmotic pump
(flow rate 0.5µl/h). The pumpwas then (after experimental week
2) exchanged with a pre-loaded pump containing DDA (1 µM),
DDB (1 µM), or AP (as control). This pump was again replaced
after 2 weeks with a new pre-loaded pump filled with the same
substance and left in place for another 2 weeks.
Electrically-Evoked Auditory Brainstem
Responses (eABRs)
To monitor the electrical responsiveness of the spiral ganglion
neurons, eABRs were measured weekly. The animal was
anesthetized and placed in a sound proof box. The eABRs were
recorded using a SigGen System 2 signal analyzer (Tucker-Davies
Technologies). Responses were summed to alternate polarity
current pulses, where each pair provided charge balancing. A
total of 2048 responses to 50µs computer-generatedmonophasic
current pulses, presented at 50 pps with an alternating polarity
on each presentation were recorded from a screw placed at
the vertex at the time of implant surgery, and a subdermal
needle electrode placed subcutaneously above the bulla on
the deafened ear serving as a reference. The animal was
connected to the ground using a subdermal needle electrode
placed intramuscularly in the hind leg. The thresholds were
monitored and defined as the lowest stimulus level (in 10-
µA steps) that evoked at least a 0.3-µV replicable waveform.
When inner ear damage is severe, it is not possible to evoke
a detectable response and thus a threshold value cannot be
obtained. The threshold was in such cases given a value of
10 µA above the highest stimulus level that could evoke a
response.
Histology
After the final eABR measurements, the animals were deeply
anesthetized with pentobarbital sodium (25 mg/kg i.p.) and
transcardially perfused with saline (37◦C) followed by cold
glutaraldehyde (2.5% in 0.1 M phosphate buffer). The temporal
bone was removed and the bulla opened up to expose the
cochlea. Small fenestrations were made in the apex and the round
window membrane and the cochlea was then gently flushed
with glutaraldehyde. The cochleae were decalcified in 0.1 M
EDTA in phosphate buffer. After decalcification the cochleae
were dehydrated and embedded in JB-4 plastic (Polyscience Inc.,
Warrington, PA, USA). The cochleae were sectioned in 4-µm
thick sections. When reaching the mid-modiolar plane of the
cochlea, defined as a section in which there are distinct profiles
through six cross sections of Rosenthal’s canal, every third
section was collected. Mounting every third section was to make
sure that each spiral ganglion neuron was counted only once.
The mounted sections were stained with Paragon and prepared
for light microscopy. Six consecutive mid-modiolar sections
were chosen from each animal and the area of each Rosenthal’s
canal was measured (Sigma Scan Pro) and the number or spiral
ganglion neurons nucleus were counted. The criterion for a
guinea pig spiral ganglion neuron was a cell with a diameter
of 14–20 microns containing a nucleus present with a diameter
in the range of 7–10 microns. The average density of the spiral
ganglion neurons was then calculated.
Statistical Analysis
For the statistical analysis in the eABR study and for the
evaluation of the spiral ganglion neuron density, one-way
ANOVA was used. Data is presented as mean± SEM.
Results
Electrical Responsiveness of the Spiral Ganglion
In themodel used in the present study, the animals are chemically
deafened in order to mimic different stages of human deafness.
An intracochlear infusion of neomycin causes rapid sensory
cell loss which in turn induces a secondary degeneration of
the spiral ganglion neurons. The progressive loss of the spiral
ganglion neuron is seen as an increase in the eABR thresholds
over time, indicating a reduced electrical responsiveness of the
peripheral auditory system. This is illustrated by the blue filled
circles in Figures 1, 2: the eABR thresholds gradually increased
and at week 6 no response could be detected using the present
methods. The model thus allows testing interventions at different
functional states. In the first study, the effects of early treatment
were investigated by infusing DDA and DDB immediately after
the neomycin infusion (Immediate Treatment, Figure 1).
After deafening and 1 week of treatment there was no
difference in the eABR thresholds between the treated groups and
the control group receiving AP. Two weeks of treatment resulted
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FIGURE 1 | Recordings of the eABR measurements throughout the
experiment for Study I (Immediate Treatment). After deafening and 1
week of treatment there was no difference in the eABR thresholds between
the treated groups and the control group. Two weeks of treatment resulted in
a significant difference (p < 0.05) for all the treated groups compared to the
control group. This significance increased and at week 4 there was a
statistically significant difference (p < 0.001) for all groups compared to the
control group. This trend continued throughout the experiment. At week 6 no
electrical response could be elicited from the control group. DDA, Dendrogenin
A; DDB, Dendrogenin B; GDNF, Glial cell-line derived neurotrophic factor.
in a significant difference (p < 0.05) for all the treated groups
compared to the control group. This significance increased and at
week 4 there was a statistical difference (p< 0.001) for all groups
compared to the control group. This result continued throughout
the experiment. At week 6 no electrical response could be elicited
from the control group using the present equipment.
For comparison, a group of animals was infused with
GDNF, a neurotrophic factor known to rescue spiral ganglion
neurons and to preserve electrical responsiveness (Fransson et al.,
2010). At week 1, i.e., 1 week after deafening and subsequent
administration of DDA, DDB, GDNF or AP, the eABR
thresholds were essentially the same in all groups. However,
already at week 2 all treated groups showed significantly lower
thresholds compared to the control group that received only
AP (DDA p < 0.05, DDB and GDNF p < 0.01; Figure 1). The
thresholds in the untreated control group continued to increase
throughout the experiment and at experimental week 6 it was
not possible to elicit an electrical response. In contrast, the
thresholds in the treated groups remained almost unchanged,
especially the DDB and GDNF groups (no difference). It
should be noted that the thresholds in the DDA group were
slightly raised and thus somewhat higher than in the DDB
and GDNF groups (p < 0.01 and p < 0.001, respectively).
Interestingly, the positive effects of DDA and DDB were
maintained during the 2-week post-treatment period (weeks
5–6).
In the second study (Delayed Treatment), drug administration
was delayed by 2 weeks and thus initiated at a later stage when the
spiral ganglion degeneration can be presumed to be more severe
(Spoendlin, 1975; Versnel et al., 2007). At week 2 (i.e., 2 weeks
after deafening and before the onset of treatment), there were no
significant differences between the groups (Figure 2). However,
FIGURE 2 | Recordings of the eABR measurements throughout the
experiment for Study II (Delayed Treatment). Two weeks after deafening
and before the treatment started there was no significant difference between
the groups. At week four after two weeks treatment there was a significant
difference (DDB 1 µM = p < 0.001 and DDA 1 µM = p < 0.05) for the treated
groups compared to the control group. Week five and six show no statistical
difference for DDA1µM compared to the control group, while the DDB 1 µM
group still showed a p < 0.001 difference. DDA, Dendrogenin A; DDB,
Dendrogenin B.
at week 4 the DDB group displayed significantly lower thresholds
compared to the control group (p< 0.001). The thresholds in the
DDB group increased slightly over time but were significantly
lower throughout the experiment. The thresholds in the DDA
group continued to increase throughout the experiment but were
lower than in the control group until week 5, from that on
there was no significant difference between the DDA treated
group and the control group. From week 4 the DDA group
displayed significantly (p < 0.01) higher thresholds compared
to the DDB group. At week 6 it was not possible to elicit a
response in the control group. The highest measurable threshold
for the equipment was 180 µA. For plotting and statistical
purposes, the threshold was set to 190 µA, which is just 10 µA
above the maximal value that can be measured using the present
system.
The Spiral Ganglion Neuron Population
To correlate differences in electrical responsiveness of the
inner ear to the size of the remaining population of spiral
ganglion neurons, the density of auditory neurons at the end
of the experiments was calculated. During the investigation
of remaining Spiral Ganglion Neurons (SGN) and to confirm
the deafening morphologically, remaining hair cells were also
observed. All hair cells had degenerated except in a few animals
where remains of damaged hair cells were found in the apical part
of the cochlea. In all six of the Rosenthal’s canals the SGN density
was calculated in the basal, middle and apical parts. Statistical
differences were found between the different parts in all groups
except for the control groups (deafened, not treated). In all
Dendrogenin treated groups there was a significant difference
(p < 0.05) between the base and the apex with fewer SGNs in
the base. In the GDNF treated group the opposite was observed
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with fewer SGNs in the apex (p < 0.05). It should be noted
that even in the normal group there were statistical differences
(p < 0.05) between the base and the middle part (fewer SGNs
in the base) and between the base and apex (fewer SGNs in the
base).
As shown in Figure 3, illustrating both studies, the density
of spiral ganglion neurons was significantly reduced in all
experimental groups compared to the normal inner ear (Normal;
not deafened and not treated). In the first study, the cell
density in the GDNF group was significantly higher (p < 0.001)
compared to both Dendrogenin groups (DDA, DDB). There
were no significant differences neither between the DDA group
and the control group nor between the DDA and DDB group.
The spiral ganglion cell density was slightly but significantly
higher in the DDB group compared to the control group
(p < 0.05). Note that even with GDNF treatment, there was
a significant loss of spiral ganglion neurons compared to
the normal group. The results of delayed treatment in the
second study (Figure 2) were similar. Again, there was no
difference in spiral ganglion density between the Dendrogenin
groups and the control group. Consistently with spiral ganglion
numeration, histological analysis showed a greater loss of
spiral ganglion neuron of the Rosenthal’s canal for AP, DDA
and DDB compared to the GDNF group (Figure 3). In
Figure 4 the eABR thresholds are shown as a function of
spiral ganglion neuron density for all groups. In Study I
there was no difference between the Dendrogenin groups,
both showing slightly increased eABR thresholds compared
to the GDNF group. However, the spiral ganglion neuron
density for the Dendrogenin groups were very low compared
to the GDNF treated group. In Study II the DDA group
show very high (or not measurable) eABR thresholds and with
the same spiral ganglion neuron density as in Study I. DDB
FIGURE 3 | The spiral ganglion neuron density in different experimental
groups. In Study I, the cell density in the GDNF study was significantly higher
(p < 0.001) compared to both Dendrogenin groups. There was no significant
difference, neither between the DDA and DDB groups, nor between the
control group (AP) and DDA. There was a significant difference (p < 0.05)
between the DDB and the control group. Study II displayed no difference
between the two Dendrogenin groups and the control group. DDA,
Dendrogenin A; DDB, Dendrogenin B; GDNF, Glial cell-line derived
neurotrophic factor.
FIGURE 4 | Scatterplot showing the eABR thresholds from all groups
as a function of the corresponding spiral ganglion neuron density.
DDA, Dendrogenin A; DDB, Dendrogenin B; GDNF, Glial cell-line derived
neurotrophic factor.
on the other hand displayed slightly higher eABR thresholds
compared to Study I but still very low spiral ganglion neuron
densities.
Discussion
The Dendrogenins represent a new group of compounds with
demonstrated effects on neural tissue. For example, these
steroidal alkaloids have been shown to have a positive effect on
neural outgrowth on PC12 and P19 cells in vitro (deMedina et al.,
2009). These compounds also trigger neuritogenesis on neural
progenitor cells. However, the Dendrogenins have previously not
been tested in vivo.
In the first study, we demonstrated the positive effects
of these compounds on the electrical responsiveness of the
peripheral auditory system in vivo. As shown in Figure 1 the
effect of DDB was about the same as for GDNF: the eABR
thresholds were essentially unchanged, indicating preserved
electrical responsiveness of the spiral ganglion. It should be
noted that the positive effect was maintained for at least 2 weeks
following the cessation of DDB (or GDNF) administration. This
has previously been shown for GDNF (Fransson et al., 2010)
and other neurotrophic factors (Agterberg et al., 2009; Jørgensen
et al., 2012). For DDA, the effect was slightly weaker compared
to DDB and GDNF but the thresholds were still significantly
better than the control values. Also with DDA, the thresholds
were maintained during the 2-week follow up period.
In the second study, treatment (infusion of DDA and DDB)
was not initiated until 2 weeks following deafness (Delayed
Treatment) in order to create a functional state more closely
resembling a clinical situation with a more permanent hearing
loss. Already at 2 weeks there are significant differences between
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deafened animals and normal animals: the eABR thresholds are
much higher. At this stage the loss of spiral ganglion neurons is
estimated to be at least 20% (Fransson, unpublished data). It is
obviously more challenging to intervene with the degeneration
process at a later stage compared to the acute situation as in
study 1 (Immediate Treatment). When DDB infusion started
after 2 weeks deafening, the eABR thresholds were clearly much
better than in the control group (Figure 2). DDA administration,
in contrast, had significantly less effect.
While the effect of Dendrogenins (especially DDB) on
the electrical responsiveness was quite similar to what has
been shown for GDNF and other trophic factors (Yamagata
et al., 2004; Shepherd et al., 2005; Agterberg et al., 2009;
Fransson et al., 2010; Jørgensen et al., 2012), the histological
findings were unexpectedly different. The density of spiral
ganglion neurons in the animals infused with DDA and
DDB was about the same as with AP (Figure 3). These
results highlights that, independently of spiral ganglion neuron
density, Dendrogenins induce additional changes improving the
electrical responsiveness of the auditory nerve. One possible
explanation is the capacity of Dendrogenins to promote axonal
preservation or growth leading to a higher number and/or quality
of the neural connections with the sensory cells and improved
cochlear implant efficacy.
During the last decades there have been several reports based
on studies of temporal bones from patients with severe to
profound sensorineural hearing loss who during their lifetime
had received a cochlear implant (Khan et al., 2005; Nadol and
Eddington, 2006). These studies suggest, when combining the
structural information with different outcome measures, e.g.,
audiometry, word recognition, and speech-reception, that there
is in fact a very weak correlation between the size of the spiral
ganglion neuron population and the functional efficacy of the
cochlear implant. The regeneration of nerve fibers allowing
a greater proximity of the nerve endings to the electrodes
has been considered as a therapeutical option to improve the
efficacy and functional benefit of cochlear implant (Shibata
et al., 2011). This approach is also of therapeutical interest
for auditory neuropathy which results from nerve degeneration
without inner hair cells loss. Based on an increasing number
of primarily experimental studies demonstrating positive results,
pharmacological treatment of the inner ear is emerging as a
highly interesting clinical tool. A wide range of substances
have been tested experimentally. Most reports involve different
neurotrophic factors, and demonstrating that these compounds
not only protect and maintain the spiral ganglion neuron
population after inner ear trauma but also maintain the neural
electrical responsiveness (Fransson et al., 2010; Landry et al.,
2011; Budenz et al., 2012; Jørgensen et al., 2012; Ramekers
et al., 2012). Other substances that have been investigated
for inner ear effects are antioxidants (Le Prell et al., 2007;
Ewert et al., 2012) and steroids (Takemura et al., 2004).
Clinical studies have primarily focused on steroids (Kopke
et al., 2001; Haynes et al., 2007). These steroids can be used
within few hours following the trauma to limit death of
hair cells and neurons, but long term actions are needed.
Dendrogenins present some advantages in comparison with
drugs previously described to improve cochlear implant efficacy.
Indeed, the poor stability of neurotrophins and the risk of
tumorigenesis (such as schwannoma) are important limitations
for their clinical use for improving cochlear efficacy. Concerning
antioxidants their potential beneficial effect appears limited
to the protection of hair cell and spiral ganglion neurons
against trauma and cannot be used after the degeneration of
spiral ganglion neuron. Moreover, we have previously reported
that DDA is a metabolite found in mammals (including
humans) and formed enzymatically (de Medina et al., 2013) The
characterization of DDB as a metabolite is under investigation
in our laboratories. Thus, we postulate that DDB could be
a metabolite involved in the maintenance of nerve functional
state and that its deregulation might be in relation with the
development of neurodegenerative diseases including hearing
loss.
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